Mahshid Sadat Ansari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mahshid Sadat Ansari has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Ifa Etesami
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
12 shared publications - Seyed Mohammad Vahabi
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Iran
12 shared publications Kamran Balighi
Autoimmune Bullous Diseases Research Centre, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
7 shared publications- Sama Heidari
Department of Dermatology, Razi Hospital Tehran University of Medical Sciences Tehran Iran
6 shared publications - Maryam Daneshpazhooh
Department of Dermatology, Autoimmune Bullous Diseases Research Center Tehran University of Medical Sciences Tehran Iran
5 shared publications Maryam Nasimi
Autoimmune Bullous Disease Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications
Latest Publications
- 20 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 457
Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study
- 20 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 457
Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study
- 3 August 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 327
Evaluating cardiometabolic risk in morphea: a case-control study with carotid imaging and metabolic assessment
- 3 August 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 327
Evaluating cardiometabolic risk in morphea: a case-control study with carotid imaging and metabolic assessment
- Open Access
- 6 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature
Introduction: Palmoplantar pustulosis (PPP) is a chronic, recurrent, inflammatory disease and assumed to be a subtype of psoriasis. Pustular psoriasis (PP) is a chronic inflammatory disease that is further subclassified into various entities with different presentations including generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPPP). Given the central role of the JAK–STAT pathway in cytokine signaling, this systematic review evaluated the effectiveness and safety of Janus kinase inhibitors (JAK‐I) in these PP subtypes. Methods: Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed/Medline, Scopus, Web of Science, and Embase up to November 13, 2025. Eligible studies included assessing JAK‐I in PPP, GPP, or PPPP. Exclusion criteria were reviews, articles without full‐text, SAPHO syndrome, and animal/in vitro studies. Risk of bias was assessed using the NHLBI quality assessment tool for clinical studies and Murad et al.'s checklist for case reports/series. Results: Thirty‐seven studies were included (29 case reports, 4 case series, and 4 clinical studies), encompassing 157 patients (60.5% female; mean age 46.8 years). Treatments involved tofacitinib, upadacitinib, baricitinib, abrocitinib, and topical ruxolitinib. In PPP, pooled meta‐analysis demonstrated a PPPASI‐50 response rate of 85.5% (95% CI, 71.3–93.3), with upadacitinib achieving 90.9% (95% CI, 81.7–95.7). Case reports and series showed 88.1% clearance or near‐clearance within a mean of 2.5 months. GPP patients ( n = 5) achieved rapid clearance or marked improvement within 2–12 weeks. Adverse events (18.7%) were generally mild, most commonly acneiform eruptions, headache, and transient liver enzyme elevations, with no severe events reported. Conclusion: JAK‐I demonstrate high response rates and rapid improvement with manageable safety profiles. However, the current evidence is limited by small sample sizes, short follow‐up durations, and reliance on case‐based data. They represent a promising therapeutic option and warrant further evaluation in larger controlled studies to establish long‐term efficacy and safety.
- 6 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Open AccessJanus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature
Introduction: Palmoplantar pustulosis (PPP) is a chronic, recurrent, inflammatory disease and assumed to be a subtype of psoriasis. Pustular psoriasis (PP) is a chronic inflammatory disease that is further subclassified into various entities with different presentations including generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPPP). Given the central role of the JAK–STAT pathway in cytokine signaling, this systematic review evaluated the effectiveness and safety of Janus kinase inhibitors (JAK‐I) in these PP subtypes. Methods: Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed/Medline, Scopus, Web of Science, and Embase up to November 13, 2025. Eligible studies included assessing JAK‐I in PPP, GPP, or PPPP. Exclusion criteria were reviews, articles without full‐text, SAPHO syndrome, and animal/in vitro studies. Risk of bias was assessed using the NHLBI quality assessment tool for clinical studies and Murad et al.'s checklist for case reports/series. Results: Thirty‐seven studies were included (29 case reports, 4 case series, and 4 clinical studies), encompassing 157 patients (60.5% female; mean age 46.8 years). Treatments involved tofacitinib, upadacitinib, baricitinib, abrocitinib, and topical ruxolitinib. In PPP, pooled meta‐analysis demonstrated a PPPASI‐50 response rate of 85.5% (95% CI, 71.3–93.3), with upadacitinib achieving 90.9% (95% CI, 81.7–95.7). Case reports and series showed 88.1% clearance or near‐clearance within a mean of 2.5 months. GPP patients ( n = 5) achieved rapid clearance or marked improvement within 2–12 weeks. Adverse events (18.7%) were generally mild, most commonly acneiform eruptions, headache, and transient liver enzyme elevations, with no severe events reported. Conclusion: JAK‐I demonstrate high response rates and rapid improvement with manageable safety profiles. However, the current evidence is limited by small sample sizes, short follow‐up durations, and reliance on case‐based data. They represent a promising therapeutic option and warrant further evaluation in larger controlled studies to establish long‐term efficacy and safety.
- 10 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (7) , 1560-1563
Beyond Autoantibodies: Identifying Clinically Relevant Biomarkers in Morphea
- 10 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (7) , 1560-1563
Beyond Autoantibodies: Identifying Clinically Relevant Biomarkers in Morphea
- 28 February 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 109
Comparative evaluation of morphea treatment response using morphea activity measure vs. LOSAI
- 28 February 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 109
Comparative evaluation of morphea treatment response using morphea activity measure vs. LOSAI
- Open Access
- 22 February 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (2) , e71891
Response to the Letter to the Editor: Unlocking Better Keloid Treatment: Corticosteroid, 5‐Fluorouracil, and Hyaluronidase vs. Corticosteroid Alone: A Randomized Comparative Study
- 22 February 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (2) , e71891
Open AccessResponse to the Letter to the Editor: Unlocking Better Keloid Treatment: Corticosteroid, 5‐Fluorouracil, and Hyaluronidase vs. Corticosteroid Alone: A Randomized Comparative Study
- Top Cited Papers
- 6 February 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 556-577
Janus Kinase Inhibitors for the Treatment of Prurigo Nodularis: A Systematic Review of 211 Patients
Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis driven by neuroimmune dysregulation for which targeted therapies are emerging. The objective of our study is to evaluate the efficacy and safety of Janus kinase inhibitors (JAK‐Is) for the treatment of PN. We conducted a systematic search in sources including PubMed/Medline, Scopus, Web of Science, and Embase; the search was completed on September 9, 2025. Inclusion criteria were the use of any JAK‐I in a patient with confirmed PN, and exclusion criteria were reviews, duplicate reports, and studies with incomplete outcome data. Risk of bias was assessed using the NHLBI quality assessment tools for observational studies and the Murad et al. checklist for case reports and case series. Ten clinical studies ( n = 180 patients) and 21 case reports/series ( n = 31 patients) were included (total n = 211). Agents evaluated included upadacitinib, tofacitinib, abrocitinib, and baricitinib. Applying standardized response criteria, 139/180 patients (77.2%) in clinical studies achieved meaningful clinical improvement. Rapid itch relief was frequently observed (days to weeks). Quality of life improved substantially (mean reduction from 20.4 to 3.9). Reported adverse events were generally mild (infections, laboratory abnormalities, dyslipidemia, acneiform eruption); serious events were rare. Limitations include small sample sizes, predominance of uncontrolled and observational designs, heterogeneity of outcomes, and limited long‐term safety data. Current evidence suggests JAK‐Is are highly effective and generally well tolerated for PN, warranting larger randomized controlled trials with extended follow‐up.
- 6 February 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 556-577
Top Cited PapersJanus Kinase Inhibitors for the Treatment of Prurigo Nodularis: A Systematic Review of 211 Patients
Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis driven by neuroimmune dysregulation for which targeted therapies are emerging. The objective of our study is to evaluate the efficacy and safety of Janus kinase inhibitors (JAK‐Is) for the treatment of PN. We conducted a systematic search in sources including PubMed/Medline, Scopus, Web of Science, and Embase; the search was completed on September 9, 2025. Inclusion criteria were the use of any JAK‐I in a patient with confirmed PN, and exclusion criteria were reviews, duplicate reports, and studies with incomplete outcome data. Risk of bias was assessed using the NHLBI quality assessment tools for observational studies and the Murad et al. checklist for case reports and case series. Ten clinical studies ( n = 180 patients) and 21 case reports/series ( n = 31 patients) were included (total n = 211). Agents evaluated included upadacitinib, tofacitinib, abrocitinib, and baricitinib. Applying standardized response criteria, 139/180 patients (77.2%) in clinical studies achieved meaningful clinical improvement. Rapid itch relief was frequently observed (days to weeks). Quality of life improved substantially (mean reduction from 20.4 to 3.9). Reported adverse events were generally mild (infections, laboratory abnormalities, dyslipidemia, acneiform eruption); serious events were rare. Limitations include small sample sizes, predominance of uncontrolled and observational designs, heterogeneity of outcomes, and limited long‐term safety data. Current evidence suggests JAK‐Is are highly effective and generally well tolerated for PN, warranting larger randomized controlled trials with extended follow‐up.
- 7 January 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 49
Paradoxical reaction to rituximab in patients with pemphigus: a systematic review of 63 patients
- 7 January 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 49
Paradoxical reaction to rituximab in patients with pemphigus: a systematic review of 63 patients